Tag Archives: HEA

PR Newswire

Thomson X Inks Strategic Partnership with Singapore-Based Startup Plano and Set Sights on Managing Myopia in Asia

Leave a comment

SINGAPORE, Feb. 5, 2021 — Thomson X ("TX"), a wholly-owned subsidiary of SGX Mainboard-listed Thomson Medical Group Limited (the "Group"), today announced a strategic partnership with Plano Pte Ltd ("Plano"), a Singapore-based HealthTech startup. The collaboration will leverage on the respective strengths of TX and Plano to address and manage the rapidly increasing incidence of myopia through innovative technological solutions.

Myopia is steadily growing into one of the biggest public health challenges in the world, affecting an estimated 2.6 billion people globally, or about one-third of the world’s population. By 2050, myopia is projected to affect 5 billion people, which is estimated to be about half of the world’s population[1]. Developed economies in Asia such as Singapore, Hong Kong, Taiwan and South Korea have reported myopia rates of more than 80% and the estimated direct annual costs of managing myopia globally amounts to US$328 billion[2].  

Plano is a health technology company that specialises in myopia management through education and awareness, innovative technological solutions and AI. Supported by the Singapore National Eye Centre, Singapore Eye Research Institute, National Health Innovation Centre and Enterprise Singapore, together with its recent strategic alliance with Santen Pharmaceutical Co., Ltd., a global ophthalmic leader, Plano is a leading advocate in raising awareness and educating the public on myopia, its risk factors and management strategies.

Thomson X, a platform that is focused on simplifying healthcare through technology, oversees Thomson Medical Group’s technology roadmap by connecting HealthTech startups with its healthcare expertise and network to scale up rapidly and maximise their reach, creating sustainable growth. Through the partnership, the Group’s patients at Thomson Paediatric Clinic and Thomson Kids in Singapore, and Thomson Eye Centre in Malaysia will soon have access to Plano’s innovative eye-care solutions on top of Thomson’s existing healthcare services. In addition, the partnership will also accelerate Plano’s market potential through TX’s global partner, the Global Esports Federation, by delivering innovative eye health services to Esports athletes and gamers who are exposed to long screen time.

The partnership will grant TX an option to subscribe for an equity stake in Plano which can be exercised in three tranches over a six-year period based on certain conditions. If all three tranches are exercised, TX will hold a minority stake in Plano, allowing TX to participate in Plano’s future growth.

References:

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.

2. World Health Organization. The impact of myopia and high myopia: Report of the Joint World Health Organization – Brien Holden Vision Institute Global Scientific Meeting on Myopia. University of New South Wales, Sydney, Australia: 2015.

ABOUT THOMSON X

Thomson X is a platform focused on enriching the current healthcare landscape through strategic partnerships and collaboration, so as to drive growth in the health and wellness space. Operating in synergy with Thomson Medical Group’s core activities and top-tier partners, Thomson X will fuel innovative health technology companies to maximise their potential. At Thomson X, we embrace the spirit of spontaneity, creativity and passion. Thomson X is a subsidiary of Thomson Medical Group

For more information, please visit: www.thomson-x.com

ABOUT PLANO

Plano was developed with a clear purpose; to save sight and empower lives. With a culture of disruptive thinking grounded in real scientific research, Plano promotes the use of education and awareness, innovative technological solutions and AI to help manage myopia & excessive device use. Plano’s founding Managing Director, Associate Professor Mohamed Dirani, is dedicated to the study and research of myopia and is an Adjunct Associate Professor at Duke-NUS Medical School and an Honorary Principal Investigator at the Singapore Eye Research Institute (SERI) and the Centre for Eye Research Australia (CERA). In July 2020, Plano announced its strategic alliance with global ophthalmic leader, Santen Pharmaceutical. In Nov 2020, Plano emerged as the winner of Galen Growth’s World’s Most Innovative HealthTech Startup 2020 Award from a field of 64 global HealthTech Startups.

For more information, visit Plano.co

PR Newswire

DFI Joins Hands with German ACL to Develop Substantial Business Opportunities in the Smart Medical Market

Leave a comment

TAIPEI, Feb. 5, 2021 — DFI, a leading industrial computer manufacturer, has entered a strategic alliance with ACL, a well-known German medical IT hardware manufacturer, and will combine with DFI’s 40 years of rich experience in industrial computers. ACL has been famous in the medical personal computer market since 1995. With profound expertise in medical IT hardware for ICU/IMC and digital operating rooms, both will join hands to open up tremendous business opportunities in the smart healthcare market.

With over 25 years of "Made in Germany" quality, ACL’s rugged and durable medical computer products are widely used in 29 out of the 37 university hospitals in Germany and deployed in many well-known medical institutions in Europe. ACL also manufactures medical-related products for many world-renowned brands such as Dräger, Olympus, eSATURNUS (Sony Group), ATMOS, XION, Cascination, Zimmer Biomet, Humanscale, and HT Group. In the initial stage, DFI will support ACL in selling their medical product portfolio in America and APAC. 

"DFI and ACL, the leaders in the smart medical market, are cooperating to create smart healthcare solutions. It is hoped that these high-quality products will open up endless business opportunities and help the medical system overcome the difficult challenges brought about by an aging society," said Steven Tsai, DFI’s President.

"For seven years, we have worked together with DFI. This strategic partnership can help us to get the latest technologies from Taiwan and faster integration into our custom-made products to the medical field," said Thomas Wollesky, ACL’s CEO.

The medical and health industry is entering a critical period of digital transformation. The alliance between DFI and ACL hopes to make an effort to improve the quality of healthcare in an aging society.

About DFI

Founded in 1981, DFI is a leading global provider of high-performance computing technology across multiple embedded industries. Smart medical applications are critical to medical quality will also be a new field where DFI will bring more contributions to an aging society.

About ACL

ACL has been manufacturing specialized IT hardware solutions for medicine and hygienically critical areas such as digital operating rooms, digitalization in intensive care units, telemedicine, and mobile solutions at its headquarters in Leipzig, Germany since 1995. Faultless and durable products are both an incentive and obligation for all ACL employees.

PR Newswire

ILIAS Biologics announces the 2nd POC study, showing anti-inflammatory effects of ILB202 on preterm birth

Leave a comment

– The study provides a novel approach to treat the fetus as a patient with an innovative drug delivery system via exosome

– ILIAS proves the expandability of its pipeline with the second POC study result using its EXPLOR® technology

DAEJEON, South Korea, Feb. 2, 2021 — ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIAS’s anti-inflammatory exosomes developed through its EXPLOR® platform technology.

This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosome (ILB202) from ILIAS Biologics, Inc. In April 2020, the researchers at the Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosome’s substantial efficacy in the septic mouse model in Science Advances(Link: https://advances.sciencemag.org/content/6/15/eaaz6980). With this second POC study showing anti-inflammatory effects on premature birth, ILIAS Biologics, Inc. proved its pipeline’s expandability using EXPLOR®.

Preterm birth is the leading cause of infant deaths, and rates are increasing over the past few decades. Infection and inflammation in the uterus are known to cause preterm birth and affect fetal mortality. Several studies are set out to explore new drugs inhibiting the inflammatory transcription factor NF-κB. Very few of these studies have progressed to clinical trials, and none are clinically in use.

Using an innovative technology called EXPLOR®, Exosomes engineering for Protein Loading via Optically Reversible protein-protein interaction, researchers in this study have injected the engineered exosomes that contain an inhibitor of NF-κB, super-repressor IκB(ILB202) into the maternal side. These engineered exosomes carrying an anti-inflammatory drug can cross the placental barrier through the mouse model’s maternal bloodstream and reach the fetus, which is an innovative approach to effectively deliver the medicine to the fetus and prevent the preterm birth. This study has suggested novel therapeutics for delaying preterm birth and increasing the survival rate of the fetus via regulation of inflammatory cytokine expression and activation of inflammatory cells in maternal and fetal tissues by ILB202 exosome delivery.

"Exosomes are natural nanoparticles or vesicles in our bodies, and we have trillions of them circulating through us at all times. By packaging the medicine inside a bioengineered exosome and injecting it into the mother intravenously, the exosomes travel through the blood system, cross the placental barrier and arrive in the fetus, where they deliver the medicine," explains Dr. Ramkumar Menon, the corresponding author of the study and a professor in UTMB’s Department of Obstetrics and Gynecology and Cell Biology.

"The study result suggests the possibility of the safe and effective treatment to prevent preterm birth by solving the problem of current medications – that cannot cross the placental barrier – with EXPLOR® technology and proves the enormous expandability of exosome-based treatment," said Chulhee Choi, CEO at ILIAS Biologics, Inc.

ILIAS is investing the proceeds of successful series B funding in 2020 to advance its platform technology and manufacturing capability, backed up by its strong R&D capability and intellectual properties. The company is also in active discussion with multiple global pharmaceutical companies for R&D collaboration and potential licensing out of its lead pipelines. Its successful POC study results have been published by international journals, and EXPLOR® technology has been granted the patent in the United States last July. Recently, ILIAS selected initial public offering (IPO) organizers and completed pre-audit aiming IPO in 2022.

Preterm Birth:

Preterm birth is when a baby is born too early, before 37 weeks of pregnancy have been completed. In 2019, preterm birth affected 1 of every 10 infants born[i]. According to World Health Organization, an estimated 15 million babies are born preterm, and 1 million among them die every year. It is estimated that 80% of death and half of neurological complications in infants are caused by preterm birth.  

There are no medications to delay preterm birth and intervene in premature labor but only temporary measures to stop labor to improve a premature baby’s prognosis. The global market size of medication to prevent and manage preterm birth is estimated at $1.1 billion (US dollar) in 2019, and it is estimated to grow to $2.8 billion in 2029. In the United States, it takes $20,000 to $100,000 for treatment/management of a premature baby, and total annual spending in the United States amounts to $26.5 billion[ii].

Exosomes: 

Exosomes are a type of extracellular vesicles, sized from 50nm to 200nm, released by cells in the body. Exosomes act as intercellular messengers delivering a variety of materials including RNA, Proteins, etc. Due to this unique function as a messenger between cells, exosomes are developed as treatments and a novel drug delivery system to carry drugs into the target cells in various diseases with significant unmet medical needs.  

ABOUT ILIAS Biologics, Inc.:

ILIAS Biologics, Inc. was established in 2015 in South Korea to develop exosome-based therapeutics. Its platform technology, EXPLOR®, makes it possible to load large therapeutic molecules into exosomes. ILIAS Biologics, Inc. is actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory, metabolic areas, and oncology. To learn more about ILIAS Biologics, Inc., visit the website at www.iliasbio.com. 

ABOUT EXPLOR® technology:

EXPLOR® technology is a novel protein-loading method that enables the active loading of large therapeutic cargo proteins into the lumen of exosomes—nanosized extracellular vesicles—through cellular biogenesis processes. This process involves controllable and reversible detachment of cargo proteins from the membrane of exosomes once they load into exosomes, which increases the efficiency of delivery of payload proteins into the cytoplasm or nucleus of target cells. While exosomes have been actively studied as novel therapeutic vehicles for intracellular drug delivery, the controllable loading of therapeutic cargo proteins as free forms in the exosomal lumen has remained a technical hurdle. ILIAS’s technology provides a unique solution to overcome this challenge and is expected to provide solutions for treating various diseases with significant medical unmet needs. The technology has been first published by Nature communication in 2016, and ILIAS has provided its first POC study result in sepsis in Science Advance in Apr. 2020. EXPLOR® technology has been granted the patent in the United States (July 2020) and in South Korea (May 2017). IILAS has applied for the patents in 7 other countries including Japan, China, India and Europe.

[i] (Ref. WHO, GLOBAL PRETERM BIRTH ESTIMATES, http://ptb.srhr.org) & (Ref. WHO, Born too soon: the global action report on preterm birth, 2012, WHO | Born too soon)

[ii] (Ref. Future Market Insights, 2020)

Related Links :

http://www.iliasbio.com/

PR Newswire

Annie Grace Offers Advice for Tackling FebFest

Leave a comment

"This Naked Mind" author shares gentle wisdom and insight 

DENVER, Feb. 1, 2021 — Taking a break from something that isn’t good for you is always a good idea. Even better when you can raise money for an important cause at the same time. In asking people to abstain from alcohol for a month and raise money for disadvantaged youth, FebFest does both.

Annie Grace, author of "This Naked Mind" and "The Alcohol Experiment"
Annie Grace, author of "This Naked Mind" and "The Alcohol Experiment"

For some, the energy behind the importance of the fundraising mission will be enough to sustain their commitment to remaining alcohol free. For others, losing the booze will be more difficult.

"Starting a month-long challenge to abstain from alcohol is exciting and empowering," says Annie Grace, author of This Naked Mind and The Alcohol Experiment. "But, it can also be daunting. If alcohol is typically part of your daily life, removing it can be difficult. And, relying on willpower alone to drive your success can make it even harder."

Annie Grace offers the following advice to anyone taking a break from alcohol:

Be Kind – First and foremost, meet yourself with compassion, right where you are. Remember, alcohol is an addictive substance. It’s OK if abstaining is hard. There is nothing wrong with you.

Buddy Up – Don’t go it alone. There is strength in numbers. Find an accountability partner or even an entire community of people on the same journey. Support and learn from each other.

Get Curious – Don’t ignore alcohol this month. Rather, use the break to truly explore your relationship with alcohol. Learn how alcohol interacts with your brain and why simply flexing your willpower muscle might not be enough.

Write It Down – Document your experience in a journal. How do you feel? What was hard? What was easy? What did you notice about yourself without alcohol? What makes you want to drink? 

Don’t Quit – If you slip and have a drink, try again. Even though it’s meant to be a month of abstinence, you do not have to declare defeat. Keep going. Do the best you can.

No matter why someone decides to participate in an alcohol free month, ultimately the best thing about their choice is the opportunity they give themselves to learn more about who they are both with and without the substance and determine what role they want alcohol to play in their lives in the future. 

About This Naked Mind
Founded by Annie Grace in 2015, This Naked Mind (TNM) helps people end the conflict between their desire to drink less and their unconscious belief that alcohol is beneficial. Annie Grace overcame a decade of drinking by revamping her own relationship with alcohol. Today she helps others across the globe do the same – the 200,000+ people who’ve bought her books, the 350,000+ people who receive daily emails from her, the listeners who’ve downloaded her This Naked Mind Podcast episodes more than 8 million times, and the 200,000+ people who’ve gone through her free program, The Alcohol Experiment. Rather than teaching people how to be sober, TNM takes away the desire to drink. And, the approach helps people where rehabs have not. Join TNM on Facebook, Instagram, YouTube, Twitter, LinkedIn, and Pinterest.

Photo – https://techent.tv/wp-content/uploads/2021/02/annie-grace-offers-advice-for-tackling-febfest.jpg

Related Links :

http://www.thisnakedmind.com

PR Newswire

Taiwan’s innovative technology allows for germ eliminating fabric by making use of semiconductor mechanics

Leave a comment

TAIPEI, Jan. 29, 2021 — With COVID-19 becoming more deadly with mutations and secondary infections becoming more frequent, people have shifted our focus from using protective masks to rushing and cutting lines to get the new vaccine. A company has created a textile that is about to be a game changer in our virus invested world. A few days ago, ACTife released a new technology for antibacterial fabric. These textile materials utilize semiconductor sputtering technology, which uses silver, copper and titanium sputtering to produce a hydroxyl radical on the surface of the fabric. Because hydroxyl radicals can destroy viruses and bacteria in medicine and make their proteins lose their function. Therefore, the materials developed by ACTife can not only block viruses and bacteria, but also use hydroxyl radicals to prevent contact with the bacteria and viruses while they are adsorbed on the surface of the fabric. This technology has been verified by the SGS, Boken, Intertek, and Japan SEK to effectively sterilize 99.9% of bacteria and germs. FYI https://health-ecoforum.medium.com/ 

The research team of Fu Jen Catholic University Taiwan published an anti-virus research report on ACTife’s nano sputtered fabric and Stated "The fabric successfully blocked and absorbed the germs and bacteria on the cloth, which prevented secondary infection of the virus." M. L.Chang, Chairman of ACTife, said: "This sputtering technology was originally used in semiconductors. When the pandemic broke out, our research team discovered that the three-metal nano-atoms of silver, copper and titanium used in medical materials had an excellent sterilization effect, so we began to develop products such as masks and protective gears. We look forward to this technology and what it can contribute to global pandemic prevention." This technology generates free radicals which causes the side chains of amino acids on the surface make proteins lose their function, thereby making germs harmless and greatly reducing the risk of infection. Not only can it apply to masks, but anything that uses fabric like towels, socks, clothing or air filters. CEO of ACTife Dr. Y. P. Lu also pointed out: "The advantage of physical antibacterial properties is that it makes the material more durable and does not precipitate any toxic or undesirable substances. As of now, the most used antibacterial chemical is bleach and the substance of bleach is actually a high concentration of sodium hypochlorite, which is well known for killing germs but it is harmful to the human body and the environment in terms of smell and touch.

The silver, copper, and titanium with splashes of ACTife Plating technology is a physical antibacterial technology that produces a free radical shield on the surface of the fabric. This highly active free radical shield eliminates bacteria and viruses that pass through it. It has the excellent function of long-lasting and washable resistance. In addition, the surface of the material does not stick to bacteria and viruses, and can be safely reused. Compared with ordinary masks and protective clothing on the market, it is not only more environmentally friendly, but also does not cause pollution and other infection risks. With its innovative antibacterial and antiviral technology, Actife has now entered the medical material market and is looking to use their innovative technology to further enhance our protection against coronavirus. ACTife website: https://www.actife.com.tw/

Related Links :

https://www.actife.com.tw

PR Newswire

iHerb Experiences Explosive Growth During COVID

Leave a comment

Global health and beauty e-commerce leader iHerb meeting unprecedented customer demand as worldwide pandemic sparks massive sales

PASADENA, Calif., Jan. 29, 2021 — iHerb is responding to explosive worldwide customer demand, including record-breaking U.S. sales, as people seek to boost their immunity, improve their health, and stay safe at home during the global COVID-19 pandemic that continues to worsen in many countries and the United States.

"The trust our millions of customers around the world place in us to safely deliver the highest quality natural products directly to their homes during the worst public health crisis in our lifetime fills all of us at iHerb with a renewed sense of urgency, responsibility, and purpose," says iHerb Logistics Chief Operating Officer, Miriee Chang.

To meet dramatically increased orders, iHerb will open a new distribution center in Hong Kong, Russia, and GCC countries, and is adding additional technology to existing warehouses within the United States. All iHerb distribution centers are kept at a cool, climate-controlled environment of 74-75 degrees Fahrenheit (23-24 degrees Celsius), and have a large walk-in refrigerator and freezer for items such as certain acidophilus products that need to be kept refrigerated or frozen. All facilities are also Good Manufacturing Practice (GMP) registered.

iHerb takes multiple precautions to protect employees at all facilities from exposure to coronavirus, and the company recently instituted a flexible remote work option for those whose jobs allow them to do so, as well as provide safe office spaces for those who need to meet in person.

"We are honored to provide an incredibly wide selection of the freshest natural products, shipped quickly around the planet to empower the health of millions of people who depend on us every day," says iHerb President, Emun Zabihi.

iHerb customers write about one million new product reviews each month about items they have verifiably ordered from the company and can contact a customer service representative with any questions 24/7.

The deep care iHerb pays to its customers also extends to its employees. iHerb was recently a first time winner of 2021 Top Workplaces USA as awarded by the United State’s most credible employer recognition program. This most recent honor comes just a month after the company earned certification as a Great Place to Work®.

Top Workplaces USA recognition is based solely on extensive surveys of employees and their honest workplace feedback. There are no subjective elements to the process, making Top Workplaces the most authentic, transparent employer recognition program in the United States.

Recent employee surveys showed 82% of iHerb team members said the company is a great place to work. Additionally, 95% of team members said work locations are safe, and more than 93% of team members said everyone is treated fairly, regardless of their gender, sexual orientation, or race.

iHerb continues to seek qualified, passionate employees to join the global team and further its commitment to serve millions of customers who depend on committed iHerb employees for their vital health needs.

About iHerb: iHerb is one of the largest US-based e-commerce retailers offering 30,000 products from 1,200 top brands to millions of customers around the world. iHerb ships directly from GMP certified, state-of-the-art climate controlled warehouses to customers in 188 countries and territories. Since 1996, iHerb has continued to innovate in bringing the highest quality products, at the best possible value, delivered with the most convenient customer experience. https://www.iherb.com

Logo – https://techent.tv/wp-content/uploads/2021/01/iherb-experiences-explosive-growth-during-covid.jpg  

Related Links :

http://iHerb.com

PR Newswire

2021 Japan Prize Laureates Announced

Leave a comment

TOKYO, Jan. 29, 2021 — The winners of the 2021 Japan Prize were announced on January 29 by the Japan Prize Foundation and its president, Hiroshi Komiyama. The newest laureates are Australian researcher Prof. Martin Andrew Green, honored for his work in the field of "Resources, Energy, the Environment, and Social Infrastructure," and U.S. researchers Prof. Bert Vogelstein and Dr. Robert A. Weinberg, joint winners for their work in the field of "Medical Science and Medicinal Science."

– In the field of Resources, Energy, the Environment, and Social Infrastructure

Prof. Martin Andrew Green:
https://kyodonewsprwire.jp/img/202101139691-O1-aQv3J84r

– In the field of Medical Science and Medicinal Science

Prof. Bert Vogelstein:
https://kyodonewsprwire.jp/img/202101139691-O2-mi5iCHaU

Dr. Robert A. Weinberg:
https://kyodonewsprwire.jp/img/202101139691-O3-nF44s3aw

Prof. Green is being honored for his work in developing high-efficiency silicon photovoltaic devices, while Prof. Vogelstein and Dr. Weinberg are being honored for their pioneering contributions to the development of a multi-step carcinogenesis model, and to the model’s application and its impact on improving cancer treatment.

Approximately 14,000 prominent scientists and engineers from Japan and other countries were approached for nominations for this year’s Japan Prize, and they nominated 142 individuals in the field of Resources, Energy, the Environment, and Social Infrastructure, and 243 individuals in the field of Medical Science and Medicinal Science. This year’s Japan Prize laureates were selected from among those 385 nominations.

Please visit:
https://www.japanprize.jp/en/index.html

PR Newswire

Alfasigma to expand its digital footprint

Leave a comment

Online doctorAsyou, a web platform entirely dedicated to physicians

The website optimizes research on the most important and autoritative medical databases such as Pubmed, ICTRP and ClinicalTrials.gov.

An entirely new area presents online courses for physicians on several different topics

BOLOGNA, Italy, Jan. 29, 2021 — Alfasigma has recently launched a number of digital activities that expand its web presence and improves its touchpoints around the world.

doctorAsyou – online at www.doctorasyou.com – is a web portal entirely dedicated to physicians with two main areas: online scientific research and medical training development.

The Website database optimizes and simplifies online research process of scientific medical information, for a continuous updating, necessary to face clinical decisions in the best possible way.

The database is updated daily and returns a total of about 30 million abstracts, combining the three most authoritative databases in the world such as PubmedICTRP  and ClinicalTrials.gov.

This comprehensive database is able to discover articles and original researches, keeping users up to date with health and medical developments in order to stay ahead and improve patient care. It’s available also a virtual library, useful to    manage in different folders all saved publication and search interests. doctorAsyou is focused on first-hand clinical information, in fact it filteres out non relevant documents types from PubMed (e.g. video, editorials, books) and improves with other sources.

Pier Vincenzo Colli, CEO of Alfasigma declares: "doctorAsyou is a relevant investment that Alfasigma has done in favor of the global scientific community in order to facilitate research work and continuous medical development of healthcare professionals. It’s another important step in our digital transformation entirely dedicated to serve psysicians and reserarrchers around the world. The scope goes beyond our focus in gastro-intestinal, vascular and rheumatological therapeutic areas, because also this project is consistent with our corporate social responsibility effort to support research and development in all scientific areas."  

The second area is made up with high-level training programs that permit to advance professional careers and build users’ confidence with a 3-6 month action-oriented learning experience made up of cohort and self-paced courses, designed and taught by a global experts community. Educational activities are delivered in a wide variety of formats that are intended to facilitate paying attention and remembering what is learned. At the same time the courses can be attended anytime and anywhere. A number of topics are covered such as Writing in Science, Medication Adherence Definition, Tools, & Statistics, Internet of Medical Things in Healthcare, Communication Skills For Surgeons, A Data-Driven Approach to Improve Patient Care and others.

More info.

Pubmed comprises over 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. PubMed citations and abstracts include the fields of biomedicine and health, covering branches of the life sciences, behavioral sciences, chemical sciences, and bioengineering.

ICTRP: International Clinical Trial Registry Platform is a service set up by the World Health Organisation (WHO) to ensure that information regarding clinical trials is accessible to all those involved in healthcare decision making.

Clinicaltrials.gov: it’s a database of privately and publicly funded clinical studies conducted in 50 states and in 216 countries. ClinicalTrials.gov is a resource provided by the U.S.  national Library of Medicine and it includes around 350,000 research studies.

About Alfasigma

Privately owned, Alfasigma is one of the leading Italian pharmaceutical companies, present in over 90 countries, through distributors and subsidiaries and has a workforce of around 3,000 people, R&D laboratories, and 5 production plants.

In Italy, Alfasigma is a leader in the market for prescription products where, in addition to the strong focus on gastrointestinal, it is present in many primary care therapeutic areas. Alfasigma also produces and markets self-medication products, nutraceuticals and food supplements.

More information is available at the corporate website https://www.alfasigma.com    

Logo – https://techent.tv/wp-content/uploads/2021/02/alfasigma-to-expand-its-digital-footprint.jpg

Related Links :

https://www.alfasigma.com/

PR Newswire

Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025

Leave a comment

Global healthcare revenues in 2025 will exceed $2.6 trillion propelled by AI and telehealth, finds Frost & Sullivan

SANTA CLARA, Calif., Jan. 28, 2021 — Frost & Sullivan’s recent analysis, Vision 2025—Rising Healthcare Expenditures and Disproportionate Improvement in Patient Outcomes Spur Disruptive Changes in the Global Healthcare Industry, forecasts that global healthcare revenues in 2025 will exceed $2.6 trillion, up from $2 trillion in 2020. Catalyzed by the COVID-19 pandemic, the industry has adopted radical new advancements in artificial intelligence (AI) and telehealth, along with new business models to support the rapid transformation. It is primed to witness a revolution in healthcare delivery over the next decade.

Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025
Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025

For further information on this analysis, please visit: http://frost.ly/570.

"The global healthcare industry is in the midst of a major shift, a process that was accelerated by the COVID-19 pandemic. Mega Trends such as anytime, anywhere care and healthcare consumerism, as well as disruptive technologies like AI and the internet of things have converged to reshape the healthcare ecosystem," said Siddharth Shah, Healthcare Program Manager at Frost & Sullivan. "Technology adoption has been at an all-time high, with the application and development of new use cases such as hospital-at-home. These tech-based tools, along with the rising penetration of smartphones and the internet, will further revolutionize healthcare delivery."

Shah added: "Rising healthcare costs and a reduction in face-to-face consultations have led to patients using digital patient engagement tools to manage their health virtually. Tech innovations and the change to virtual consultations are strengthening patients’ roles in clinical decision-making, reshaping care delivery, and supporting industry growth. They are expected to increase the focus toward consumer-centricity in offerings and approaches to patients, physicians, and providers as customers. Innovative startups are realizing returns on this opportunity for primary care through physical, virtual, and eCommerce methods."

For further revenue opportunities, market participants should explore these strategic recommendations:

  • Employ patient-centered virtual assistants to respond to voice or text questions through mobile devices to provide patients with constant access to current information.
  • Embed intelligence within imaging equipment to consider patient information for clinical recommendations to enable effective diagnoses of specific conditions and help determine the best treatment protocols.
  • Enable screening, diagnoses and the fulfillment of treatments through existing innovation in smart devices, mHealth wearables, apps, and diagnostics.
  • Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies.
  • Simplify genomic workflows with big data analytics platforms that automate the progress of large post-analysis data files to lower-cost storage and free up expensive, high-performance tiers for current analysis needs.

Vision 2025—Rising Healthcare Expenditures and Disproportionate Improvement in Patient Outcomes Spur Disruptive Changes in the Global Healthcare Industry is part of Frost & Sullivan’s global Transformational Health Growth Partnership Service program.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Vision 2025—Rising Healthcare Expenditures and Disproportionate Improvement in Patient Outcomes Spur Disruptive Changes in the Global Healthcare Industry
K57A-54

Contact:
Mariana Fernandez
Corporate Communications
P: +1 210 348 10 12
E: Mariana.Fernandez@frost.com
http://ww2.frost.com

Photo – https://techent.tv/wp-content/uploads/2021/01/technology-innovations-and-virtual-consultations-drive-the-healthcare-industry-transformation-by-2025.jpg

Related Links :

https://ww2.frost.com/

Frost New Home page v2

PR Newswire

Kingston x CSD Reveals APAC Top 10 heartwarming face mask designs

Leave a comment
  • Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020
  • Vote online now for the favourite finalist and decide who the winner will be

TAIPEI, Jan. 27, 2021 — Continuing with the credo of preserving memories, Kingston Technology, a world leader of memory products and technology solutions, today announced the top 10 finalists of the Kingston x CSD APAC Mask Design Competition. Centered around the theme of ‘There’s Strength in Memory,’ Kingston partnered with CSD, a leading brand of face masks, to call upon all creative minds to unleash the power of memories. The initiative received an overwhelming response of over 3,100 entries from design enthusiasts across all APAC regions.

Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020.
Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020.

The contestants comprised of APAC’s top artists and designers from various fields. ranging from product, textile, visual and multi-media designers, to illustrators, art students and professors. Their design submissions spanned a wide canvas that encapsulated their memories, concepts regarding people’s interaction, compelling and memorable life events and reflections on 2020. The judges also discovered ongoing themes of design that centered around family bonds, appreciation of nature and intimate childhood memories: Lilo Jong from Malaysia portrayed the strong bond she has with her family, while Wu Bo Yi from Taiwan found inspiration from a childhood snack; Tsuyoshi Artman, from Japan, depicted the beauty of nature to highlight the act of breathing. Despite submissions from artists with diverse backgrounds, one thing that united the contestants was the effort to represent positivity in the lives of people across regions, thus, unleashing the power of memories.

Commenting on the outstanding response, Kevin Wu, sales/marketing and business development Vice President of APAC region, Kingston, said, "Our memories are the most precious assets in our lives and we at Kingston have always strived to help our customers preserve their memories in the best way possible with our products and campaigns. Our unique partnership with CSD for the Kingston x CSD APAC Mask Design Competition, has helped us in our journey of bringing people closer with their most profound memories. We are overwhelmed to see so many contestants finding and sharing strength in their memories; their designs therefore embody deeper emotions that range from pleasant to more challenging times that they’ve encountered. Through this campaign, we are humbled to have been an intrinsic part of our contestants’ life-altering as well as inspiring moments."

Commenting on the stellar designs, Jonathan Chang, COO of CSD, said, "Over the past few years, CSD has redefined the concept of the face mask by infusing fashion elements into it. It is exhilarating to also see such innovation from the contestants. Not only have they evolved face mask into an individual canvas, but also redefined memories into a fashion statement with their brushstroke. I’m thrilled that our creative alliance with Kingston has pushed the boundaries and reinvented the notion of memory and face masks into a new form of art."

The top 10 designs were selected from over 3,100 entries, with 5 designs each under the two different judging criteria; the "3-Colors" group emphasized on creative patterns consist of only three colors, whereas the "Unlimited Colors" group stressed on how well contestants play with their colors.

The "3-Colors" Finalists:

Perfect Imperfections, Aljohn M. Matias (Philippines)
Siamese Fighting Fish, Waraporn Mamee (Thailand)
Lips & Water Chestnut, Wu Bo Yi (Taiwan)
Doodling Paper, Nguyen Dang Binh (Vietnam)
Sparkling Lenses, Rishabh Raj (India)

The"Unlimited Colors" Finalists: 

Love Memories Forever, Lilo Jong (Malaysia)
Construct X Deconstruction, Brenca Sun (Taiwan)
Summer memories in the wonder garden, Hsu, Hsing-Chen (Taiwan)
Breath of Energy, Tsuyoshi Artman (Japan)
Monster Nation, Yman.S (Malaysia)

People can now vote for their favorite designs and determine who will be the winner of the competition. Online voting starts January 27, 2021 and will end on February 7, 2021. For winner announcement for the fan-favorite awards and more details please refer to: http://kings.tn/Mask_Design_Finalists

Watch the top 10 finalists video in the pinned post here. Comment and share the video and other related social posts on Kingston’s social channels for a chance to win the exclusive Memory Box with facemasks of the top 10 designs!

Kingston can be found on:

Facebook: https://www.facebook.com/KingstonAPAC
YouTube: http://www.youtube.com/user/KingstonAPAC

Kingston – Guarding Your Memories, Kingston is With You

Kingston has consistently safeguarded people’s precious memories for 33 years with the highest quality standards. By preserving people’s memories, we have become the driving force for progressive development. Resonating our long-term values, we believe that only with "memory" growth, there can be breakthroughs in "memory" technology. Only with excellent "memory", people can become the world’s best, and as an indispensable part of their memories – ‘Kingston is With You’.

From big data, to laptops and PCs, to IoT-based devices like smart and wearable technology, to design-in and contract manufacturing, Kingston helps deliver the solutions used to live, work and play. The world’s largest PC makers and cloud-hosting companies depend on Kingston for their manufacturing needs, and our passion fuels the technology the world uses every day. We strive beyond our products to see the bigger picture, to meet the needs of our customers and offer solutions that make a difference. To learn more about how Kingston Is With You, visit Kingston.com.

CSD – Health in Style

Founded in 1947, CSD, as the leader in Taiwan for health protection supplies, we have supplied reliable and quality medical suppliers to doctors and hospitals internationally, and have become a significant player in the process. With profound changes in homecare needs over the last few decades, brought about by the likes of SARS, COVID-19, etc. CSD took their expertise and applied it to their vision for the consumer homecare market. Since 2015, CSD has created a series of fashion medical face masks, which not only deliver high levels of safety and performance, but also combines health and style to an everyday homecare product. In addition, CSD has collaborated with multiple international boutique brands, as well as special events and concerts. For decades to come, from hospitals to the street, CSD will continue to redefine standards and set new trends – ‘Health in Style’.

Kingston and the Kingston logo are registered trademarks of Kingston Technology Corporation.

Kingston and the Kingston logo are registered trademarks of Kingston Technology Corporation. IronKey is a registered trademark of Kingston Digital, Inc. All rights reserved. All trademarks are the property of their respective owners.

Related Links :

http://www.kingston.com/